NCT00651482View on ClinicalTrials.gov

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Kidney NeoplasmsKidney (Renal Cell) Cancer
Interventions
DRUG

Everolimus

DRUG

Bevacizumab

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (2)

Genentech, Inc.
Novartis
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Sandy Srinivas

OTHER

NCT00651482 - Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) | Biotech Hunter | Biotech Hunter